Vascular Biogenics Ltd. Banner Image

Vascular Biogenics Ltd.

  • Ticker VBLT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Vascular Biogenics Ltd. Logo Image
  • 11-50 Employees
  • Based in Modiin, Israel
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focusMore on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks.
4.8 / 5.0 (121)

Vascular Biogenics Ltd. reports have an aggregate usefulness score of 4.8 based on 121 reviews.

Vascular Biogenics Ltd.

Most Recent Annual Report

Vascular Biogenics Ltd.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Vascular Biogenics Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!